Overview
Kisspeptin-10 is classified as a reproductive peptide peptide. LH/FSH stimulation, testosterone support, fertility enhancement, HPG axis activation.
Endogenous neuropeptide that is the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin-10 binds to the GPR54 (KISS1R) receptor on GnRH neurons, triggering pulsatile GnRH release which stimulates LH and FSH secretion from the pituitary. This cascade drives testosterone production in males and ovulation in females. Unique advantage: activates the reproductive axis at its highest control point without bypassing natural feedback loops.
Also known as: KP-10, Metastin 45-54, KISS1
Category
Reproductive Peptide
Half-Life
0.5h
Route
SubQ
FDA Status
Not Approved
How Does Kisspeptin-10 Work?
Endogenous neuropeptide that is the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin-10 binds to the GPR54 (KISS1R) receptor on GnRH neurons, triggering pulsatile GnRH release which stimulates LH and FSH secretion from the pituitary. This cascade drives testosterone production in males and ovulation in females. Unique advantage: activates the reproductive axis at its highest control point without bypassing natural feedback loops.
At the molecular level, Kisspeptin-10 operates through pathways characteristic of the Reproductive Peptide class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Kisspeptin potently stimulates LH and testosterone in healthy men
Dhillo et al. (J. Clin. Endocrinol. Metab.): IV Kisspeptin-10 (1mcg/kg) potently stimulates LH pulse frequency and testosterone secretion in healthy men, establishing its role as a reproductive axis activator.
Evidence: moderate[2]Kisspeptin restores LH pulsatility in hypogonadal men
George et al.: Kisspeptin-10 infusion restores LH pulsatility and increases testosterone in men with type 2 diabetes-associated hypogonadism, demonstrating therapeutic potential.
Evidence: moderate[3]Kisspeptin as alternative oocyte maturation trigger in IVF
Abbara et al. (J. Clin. Invest.): Kisspeptin-54 triggers oocyte maturation in women undergoing IVF with significantly lower risk of ovarian hyperstimulation syndrome (OHSS) vs. hCG trigger.
Evidence: strong[4]Kisspeptin stimulates reproductive hormones in women
Jayasena et al.: Kisspeptin-10 administration increases LH secretion in women, with response magnitude dependent on menstrual cycle phase (strongest in preovulatory phase).
Evidence: moderate[5]Kisspeptin tachyphylaxis with continuous administration
Ramaswamy et al.: Continuous Kisspeptin-10 infusion leads to desensitization of the HPG axis within 24-48 hours, indicating pulsatile dosing protocols are necessary for sustained efficacy.
Evidence: preclinicalSafety Profile
Endogenous human neuropeptide with growing clinical trial data. Tachyphylaxis (desensitization) occurs with continuous dosing; pulsatile/intermittent protocols required. Being investigated as a safer IVF trigger (vs. hCG). Not FDA-approved for therapeutic use. Research-only.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site reaction | ~8% of users | mild |
| Mild headache | ~5% of users | mild |
| Flushing / warmth | ~5% of users | mild |
| Tachyphylaxis (with continuous dosing) | Variable | moderate |
Sourcing Kisspeptin-10 for Research
If you're looking to source Kisspeptin-10 for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
Kisspeptin-10 — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.